Introduction {#Sec1}
============

The ubiquitin-proteasome system regulates turnover of proteins involved in apoptosis, proliferation, and signal transduction \[[@CR1]--[@CR3]\]. Cullin-RING ligases (CRLs), the largest subfamily of E3 ubiquitin ligases, target proteins for proteasomal degradation through the addition of polyubiquitin chains \[[@CR2]\]. CRL activation via conjugation to the small ubiquitin-like protein NEDD8 (neural precursor cell expressed, developmentally downregulated 8) is regulated by NEDD8-activating enzyme (NAE). CRLs and associated regulatory proteins are attractive novel targets for the development of antitumor agents \[[@CR2], [@CR3]\].

Pevonedistat (TAK-924/MLN4924) is a first-in-class, investigational, small-molecule NAE inhibitor that covalently binds to NEDD8, leading to apoptotic cell death. Pevonedistat has shown single-agent activity in various human solid tumor cell lines and xenograft models, as well as in patients with advanced solid tumors and hematologic malignancies \[[@CR2], [@CR4]--[@CR12]\]. Pevonedistat delays completion of platinum-induced DNA repair in a transcription-coupled nucleotide excision repair (NER) and interstrand crosslink repair (ICR) pathway−dependent mechanism \[[@CR13]\]. Excision repair cross-complementation group 1 (ERCC1), a component of the NER pathway, is thought to be involved in resistance to platinum-based therapies \[[@CR14], [@CR15]\] and predictive of decreased efficacy of platinum therapy \[[@CR16]--[@CR21]\]. Pevonedistat enhances the antitumor activity of taxanes and gemcitabine, is synergistic with platinum salts, and is active in platinum-resistant tumors \[[@CR13], [@CR22]--[@CR24]\].

The safety and activity of pevonedistat monotherapy were investigated in a phase I study in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), which demonstrated that treatment was feasible with clinical activity \[[@CR11]\]. Additionally, the efficacy and safety of pevonedistat in combination with the standard-of-care agent azacitidine have been investigated in treatment-naïve patients with AML ([ClinicalTrials.gov](http://clinicaltrials.gov) identifier NCT01814826) \[[@CR25]\]. Phase II and III studies of pevonedistat in combination with azacitidine in high-risk MDS, chronic myelomonocytic leukemia, or low-blast count AML are currently ongoing ([ClinicalTrials.gov](http://clinicaltrials.gov) identifiers NCT02610777 and NCT03268954). To further explore the role of pevonedistat in combination with standard-of-care chemotherapies, this phase Ib study aimed to determine the maximum tolerated dose (MTD) and assess the safety, tolerability, and pharmacokinetics of pevonedistat in combination with docetaxel, carboplatin plus paclitaxel, or gemcitabine in patients with advanced solid tumors. The expression of ERCC1 as a candidate biomarker of response to treatment with pevonedistat in combination with carboplatin plus paclitaxel therapy was also investigated.

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

This was an open-label, multicenter, phase Ib, dose-escalation study of pevonedistat in combination with either docetaxel (arm 1), carboplatin plus paclitaxel (arm 2), or gemcitabine (arm 3) in adult patients with confirmed solid tumors who had progressed despite standard therapy or for whom conventional therapy was considered ineffective ([ClinicalTrials.gov](http://clinicaltrials.gov) identifier NCT01862328; Online Resource: Supplementary Fig. [1](#MOESM2){ref-type="media"} a). Patient eligibility criteria are described in the Online Resource. Patients were enrolled between 10 June 2013 and 04 May 2015 at six US centers. This study was approved by the Institutional Review Board and Independent Ethics Committee at each site and conducted in accordance with all applicable regulatory requirements, Good Clinical Practice standards, and the Declaration of Helsinki. All patients provided written informed consent.

Dose escalation in arm 1 consisted of intravenous pevonedistat at a 15 mg/m^2^ starting dose on days 1, 3, and 5 plus docetaxel 75 mg/m^2^ on day 1 of 21-day cycles. A lead-in cohort (arm 2a) of six patients received pevonedistat 15 mg/m^2^ on days 1, 3, and 5 plus carboplatin AUC~6~ (target area under the concentration-time curve of 6 mg/mL·min) on day 1 to determine the dose of carboplatin in arm 2. If two or more dose-limiting toxicities (DLTs) were reported, carboplatin dosing was to be reduced to AUC~5~, and paclitaxel be reduced from the planned 200 to 175 mg/m^2^. Patients in arm 2 received escalating doses of pevonedistat starting at 15 mg/m^2^ on days 1, 3, and 5, in combination with carboplatin AUC~5~ plus paclitaxel 175 mg/m^2^ on day 1 of 21-day cycles. In arm 3, patients received escalating doses of pevonedistat starting at 25 mg/m^2^ and gemcitabine 1000 mg/m^2^ on days 1, 8, and 15 of 28-day cycles. Planned pevonedistat doses were higher in arm 3 (versus arm 1 and arm 2) but administration was on a weekly schedule (versus three times a week in arm 1 and arm 2) to match the dosing schedule of gemcitabine, to ensure exposure to both drugs and leverage the mechanism of action of the two drugs. Full dosing details are included in the Online Resource.

Pevonedistat dose escalation (Online Resource: Supplementary Fig. [1](#MOESM2){ref-type="media"} b) proceeded via an adaptive Bayesian continual reassessment method (CRM) based on cycle 1 DLTs (Online Resource). Upon MTD determination in each arm, additional patients were enrolled to confirm the MTD (MTD expansion cohorts). Patients were treated for up to 12 cycles or until disease progression or unacceptable toxicity. Patients with clinical benefit could continue with combination treatment or single-agent pevonedistat beyond 12 cycles.

The primary objective was to establish the MTD of pevonedistat in combination with docetaxel, with carboplatin plus paclitaxel, and with gemcitabine. Secondary objectives included disease response and pharmacokinetics of pevonedistat plus standard-of-care regimens. An exploratory objective was to identify potential biomarkers of response to pevonedistat-containing therapy, including tumor ERCC1 expression.

Assessments {#Sec4}
-----------

Adverse events (AEs) were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. DLT determination criteria are described in the Online Resource. Investigator-assessed tumor responses were based on Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 \[[@CR26]\]. Response assessment methods are described in the Online Resource. Blood sampling methods for pharmacokinetic analyses, immunohistochemistry and ERCC1 expression evaluation methods, and statistical methods are reported in the Online Resource.

Results {#Sec5}
=======

Patients {#Sec6}
--------

At data cutoff (01 April 2016), 64 patients had been enrolled (22 in arm 1, six in arm 2a, 26 in arm 2, and 10 in arm 3) and had received at least one dose of study drug. Patient demographics and baseline characteristics were generally similar between arms (Table [1](#Tab1){ref-type="table"}). The median number of treatment cycles was 4 (range, 1--21), and 26 (41%) patients completed ≥5 cycles (Online Resource: Supplementary Table [1](#MOESM1){ref-type="media"}). At data cutoff, 62 (97%) patients had discontinued treatment (mostly due to disease progression \[*n* = 39\] and AEs \[*n* = 11\]). Two patients remained on study in arm 2, receiving single-agent pevonedistat 20 mg/m^2^ as maintenance.Table 1Patient demographics and baseline characteristics (safety population)Total (*N* = 64)Arm 1: pevonedistat + docetaxel (*n* = 22)Arm 2a (lead-in cohort): pevonedistat + carboplatin (*n* = 6)Arm 2: pevonedistat + carboplatin + paclitaxel (*n* = 26)Arm 3: pevonedistat + gemcitabine (*n* = 10)Gender Male / female, No. (%)30 (47) / 34 (53)9 (41) / 13 (59)2 (33) / 4 (67)13 (50) / 13 (50)6 (60) / 4 (40)Race White / Black or African American, No. (%)52 (81) / 12 (19)16 (73) / 6 (27)4 (67) / 2 (33)23 (88) / 3 (12)9 (90) / 1 (10)Median age, years (range)60.5 (26--84)61.0 (29--76)54.5 (46--72)61.0 (26--77)55.5 (42--84)Median body surface area, m^2^ (range)1.91 (1.42--2.78)1.89 (1.42--2.51)1.75 (1.47--2.18)1.96 (1.54--2.78)1.87 (1.62--2.41)ECOG PS 0 / 1, No. (%)21 (33) / 43 (67)8 (36) / 14 (64)2 (33) / 4 (67)7 (27) / 19 (73)4 (40) / 6 (60)Median time since initial diagnosis, months (range)26.6 (2.2--126.6)22.9 (2.2--126.6)34.7 (18.6--55.4)30.3 (12.9--113.4)16.5 (4.6--60.5)Most common (≥2 patients) disease type, No. (%) NSCLC, adenocarcinoma^a^13 (20)5 (23)2 (33)2 (8)4 (40) Breast6 (9)2 (9)1 (17)3 (12)0 (0) Ovarian4 (6)1 (5)1 (17)2 (8)0 (0) Head and neck^b^6 (9)2 (9)1 (17)3 (12)0 (0) NSCLC, squamous carcinoma4 (6)0 (0)0 (0)3 (12)1 (10) Cholangiocarcinoma2 (3)2 (9)0 (0)0 (0)0 (0) Colon2 (3)0 (0)1 (17)1 (4)0 (0) Melanoma2 (3)1 (5)0 (0)1 (4)0 (0) NSCLC not otherwise specified2 (3)2 (9)0 (0)0 (0)0 (0)Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance score; NSCLC, non-small cell lung cancer^a^Includes 12 patients with adenocarcinoma and one with large cell adenocarcinoma^b^Includes one patient with parotid gland carcinoma (arm 2), one with salivary gland carcinoma (arm 1), and one with squamous cell carcinoma of the oropharynx (arm 2)

DLTs and MTD {#Sec7}
------------

Fifty-six (88%) patients were included in the DLT-evaluable population (Table [2](#Tab2){ref-type="table"}). In the dose-escalation phase of arm 1, none of the three patients receiving pevonedistat 15 mg/m^2^ experienced a DLT, and two of 12 patients receiving pevonedistat 25 mg/m^2^ experienced ≥1 DLT (grade 3 increased alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]). Therefore, the MTD for pevonedistat was established as 25 mg/m^2^ in combination with docetaxel. Six additional patients (of whom five were DLT evaluable) were enrolled in the expansion portion at this dose to further characterize safety and tolerability (17 total DLT-evaluable patients), with two additional patients experiencing ≥1 DLT (grade 3 ALT/AST elevation).Table 2DLTs occurring during cycle 1 in the dose-escalation and MTD expansion phases and in the DLT-evaluable populationTreatment armPevonedistat dose, mg/m^2^No. of patientsNo. of patients with G ≥3 DLTDLTManagement of DLTsArm 1: pevonedistat + docetaxel (*n* = 20)153 (dose-escalation)0NoneNA25 (MTD)12 (dose-escalation)2G3 increased ALT + G3 increased ASTDose hold and dose reductionG3 increased ALT + G3 increased ASTDose hold and dose reduction5 (MTD expansion)2G3 increased ALTDose hold and dose reductionG3 increased ALT + G3 increased ASTDose holdArm 2a (lead-in cohort): pevonedistat + carboplatin (*n* = 6)1562G4 thrombocytopeniaDose delayed and concomitant medicationG3 increased ASTDose delayedArm 2: pevonedistat + carboplatin + paclitaxel (*n* = 22)155 (dose-escalation)1G3 febrile neutropeniaDose reduction and concomitant medication255 (dose-escalation)2G3 increased ALT + G3 increased ASTDose hold and dose reductionG3 increased AST^a^Dose hold and dose reduction20 (MTD)6 (dose-escalation)2G3 increased ALT + G3 increased ASTDose hold and dose reductionG3 increased ALT + G3 increased ASTDose hold and dose reduction6 (MTD expansion)1G3 increased ASTDose reductionArm 3: Pevonedistat + gemcitabine (*n* = 8)2583G4 febrile neutropeniaDiscontinued from studyG3 febrile neutropenia + G5 febrile neutropeniaConcomitant medication, then discontinued from studyG3 increased ALT + G3 increased ASTDose hold and dose reductionAbbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRM, continual reassessment method; D, day; DLT, dose-limiting toxicity; G, grade; MTD, maximum tolerated dose; NA, not applicable^a^DLT was not considered related to study drug but was used in the CRM algorithm to de-escalate the next dose to 15 mg/m^2^

In arm 2a, two of six patients receiving pevonedistat 15 mg/m^2^ plus carboplatin AUC~6~ experienced DLTs: grade 4 thrombocytopenia and grade 3 elevated AST. Due to the toxicity observed in this lead-in cohort, patients enrolled in subsequent arm 2 cohorts received carboplatin AUC~5~ and paclitaxel 175 mg/m^2^.

In arm 2, no DLTs were observed in an initial cohort of patients treated with pevonedistat 15 mg/m^2^. Following the CRM, pevonedistat was escalated to 25 mg/m^2^, and two of five patients experienced DLTs (grade 3 increased AST and grade 3 increased ALT and AST). This led to dose de-escalation of pevonedistat (15 mg/m^2^) and, among three additional patients enrolled at this dose level, one DLT (grade 3 febrile neutropenia) was observed. Per protocol, patients were then enrolled to an intermediate dose level of pevonedistat 20 mg/m^2^, and two of six patients had DLTs (grade 3 increased ALT and AST). Based on all DLTs to date and according to the CRM algorithm, the predicted MTD at this stage was 18.1 mg/m^2^. As the predicted MTD was between the mid~low~ (17.5 mg/m^2^) and mid~high~ (22.5 mg/m^2^) (see the Online Resource) and because at least six patients had been enrolled at the 20 mg/m^2^ dose, the CRM algorithm did not suggest further dose escalation or de-escalation and the MTD was declared as 20 mg/m^2^ (Online Resource: Supplementary Fig. [1](#MOESM2){ref-type="media"} b). Six additional patients were enrolled at this dose (expansion phase) for a total of 12 patients receiving pevonedistat at the MTD (20 mg/m^2^) in combination with paclitaxel plus carboplatin; one of these six patients reported a DLT (grade 3 increased AST), confirming the MTD in this arm.

In arm 3, eight patients enrolled at the initial dose of pevonedistat 25 mg/m^2^ were DLT evaluable and three experienced a DLT: one had grade 3 increased ALT and AST, one had grade 4 febrile neutropenia and withdrew from the study, and one had grade 3 febrile neutropenia, withdrew from the study, and died from complications of febrile neutropenia. Due to the number of DLTs observed in this arm, and based on two patients missing \>1 treatment dose in cycle 1, as well as the need to delay therapy in cycle 2 to allow recovery from gemcitabine-related myelosuppression toxicity, no additional patients were enrolled in accordance with the CRM algorithm. Pevonedistat dose de-escalation to 15 mg/m^2^ was not explored, as myelosuppression was considered related to gemcitabine. The MTD of pevonedistat in combination with gemcitabine was not determined, and this drug combination was abandoned.

Of 15 patients with cycle 1 DLTs, 10 had liver function test (LFT) elevations (increased AST/ALT), which were the predominant DLTs reported across all arms regardless of standard-of-care chemotherapy. All LFT elevations were without clinical sequelae and reversible with dose delays or holds; prior therapies for these patients are reported in the Online Resource: Supplementary Table [2](#MOESM1){ref-type="media"}.

Safety {#Sec8}
------

All 64 patients experienced ≥1 AE and 53 (83%) had grade ≥3 AEs (Table [3](#Tab3){ref-type="table"}). The most common any-grade AEs were fatigue (56%), nausea (50%), anemia (41%), constipation, diarrhea (34% each), increased AST (31%), and vomiting (30%). The most common grade ≥3 AEs were decreased neutrophil count (22%) and increased AST (20%). Overall, 95% of patients had ≥1 drug-related AE of any grade and 66% had grade ≥3 drug-related AEs (Online Resource: Supplementary Table [3](#MOESM1){ref-type="media"}). Across arms, 26 (41%) patients experienced ≥1 serious AE, including febrile neutropenia (9%), dyspnea (6%), abdominal pain, and pneumonia (3% each).Table 3Most common any-grade AEs (≥20% of all patients) and grade ≥3 AEs (≥10% of all patients) (safety population)Total (*N* = 64)Arm 1: pevonedistat + docetaxel (*n* = 22)Arm 2a (lead-in cohort): pevonedistat + carboplatin (*n* = 6)Arm 2: pevonedistat + carboplatin + paclitaxel (*n* = 26)Arm 3: pevonedistat + gemcitabine (*n* = 10)Patients with one or more any-grade AE, *n* (%)64 (100)22 (100)6 (100)26 (100)10 (100) Fatigue36 (56)12 (55)4 (67)16 (62)4 (40) Nausea32 (50)8 (36)5 (83)14 (54)5 (50) Anemia26 (41)7 (32)3 (50)12 (46)4 (40) Constipation22 (34)4 (18)4 (67)11 (42)3 (30) Diarrhea22 (34)9 (41)1 (17)11 (42)1 (10) Increased AST20 (31)6 (27)2 (33)9 (35)3 (30) Vomiting19 (30)4 (18)1 (17)11 (42)3 (30) Increased ALT18 (28)7 (32)1 (17)6 (23)4 (40) Alopecia17 (27)5 (23)1 (17)10 (38)1 (10) Decreased appetite15 (23)4 (18)0 (0)6 (23)5 (50) Decreased neutrophil count15 (23)6 (27)1 (17)7 (27)1 (10) Thrombocytopenia15 (23)2 (9)3 (50)7 (27)3 (30) Dyspnea14 (22)6 (27)2 (33)3 (12)3 (30) Neutropenia14 (22)2 (9)1 (17)9 (35)2 (20) Peripheral sensory neuropathy14 (22)3 (14)1 (17)9 (35)1 (10) Pyrexia14 (22)6 (27)1 (17)5 (19)2 (20) Arthralgia13 (20)2 (9)0 (0)9 (35)2 (20) Myalgia13 (20)3 (14)0 (0)10 (38)0 Decreased platelet count13 (20)1 (5)2 (33)7 (27)3 (30)Patients with one or more grade ≥3 AE, *n* (%)53 (83)18 (82)4 (67)21 (81)10 (100) Decreased neutrophil count14 (22)6 (27)0 (0)7 (27)1 (10) Increased AST13 (20)4 (18)2 (33)6 (23)1 (10) Anemia12 (19)3 (14)2 (33)6 (23)1 (10) Increased ALT11 (17)5 (23)0 (0)4 (15)2 (20) Neutropenia10 (16)1 (5)1 (17)7 (27)1 (10) Thrombocytopenia7 (11)0 (0)2 (33)4 (15)1 (10)Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase

Four patients (arm 2) reported AEs leading to permanent treatment discontinuation. Of these, one patient receiving pevonedistat 15 mg/m^2^ in combination with carboplatin plus paclitaxel discontinued due to thrombocytopenia, and three patients (two receiving pevonedistat 20 mg/m^2^ and one 25 mg/m^2^, both with carboplatin plus paclitaxel) discontinued due to peripheral neuropathy or peripheral sensory neuropathy.

There were five on-study deaths, including one on day 23, cycle 1 that was considered drug-related (arm 3, pevonedistat 25 mg/m^2^: febrile neutropenia). A further three patients died during cycle 1 and one died during cycle 9, all of which were considered unrelated to treatment (all pevonedistat 25 mg/m^2^; one each in arm 1 and arm 2, two in arm 3).

Pevonedistat pharmacokinetics {#Sec9}
-----------------------------

Figure [1](#Fig1){ref-type="fig"} compares the dose-normalized pevonedistat concentrations for patients receiving pevonedistat in combination with docetaxel (*n* = 16, dose-escalation; *n* = 6, MTD expansion), carboplatin plus paclitaxel (*n* = 20 dose-escalation; *n* = 6, MTD expansion), or gemcitabine (*n* = 10) with those from patients who received single-agent pevonedistat in previous studies \[[@CR7]--[@CR9], [@CR11]\]. Examination of individual patient plasma concentration-time data (Fig. [1](#Fig1){ref-type="fig"}a and c) revealed no significant changes in pevonedistat pharmacokinetics when given with docetaxel (arm 1) or gemcitabine (arm 3), as the observed pevonedistat concentrations in the presence of docetaxel or gemcitabine showed considerable overlap with those with pevonedistat alone. By contrast, following the end of infusion and throughout the 48-h sampling period, pevonedistat plasma concentrations were consistently higher in patients receiving carboplatin plus paclitaxel than in patients receiving single-agent pevonedistat (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Observed dose-normalized concentration-time profiles of pevonedistat with and without concurrent administration of docetaxel (**a**), carboplatin plus paclitaxel (**b**), or gemcitabine (**c**). The figure shows raw concentration-time data from prior studies of single-agent pevonedistat (circles) \[[@CR7]--[@CR9], [@CR11]\] and from the combination therapy in this study (crosses)

Disease response {#Sec10}
----------------

A summary of best response to treatment is shown in Table [4](#Tab4){ref-type="table"}. In arm 1, among 19 response-evaluable patients, three patients receiving the MTD achieved a partial response (PR), for an overall response rate (ORR) of 16%. Among responders, one had cholangiocarcinoma, two had head and neck cancer (squamous cell carcinoma and salivary gland carcinoma), and all three had lung metastases. One patient in arm 2a (squamous cell carcinoma of the head and neck not otherwise specified) achieved a PR.Table 4Summary of best response to treatment (response-evaluable population)Total (*N* = 54)Arm 1: pevonedistat + docetaxel (*n* = 19)Arm 2a (lead-in cohort): pevonedistat + carboplatin (*n* = 6)Arm 2: pevonedistat + carboplatin + paclitaxel (*n* = 23)Arm 3: pevonedistat + gemcitabine (*n* = 6)ORR (CR + PR), *n* (%)12 (22)3 (16)1 (17)8 (35)0 (0)CR2 (4)^a^0 (0)0 (0)2 (9)0 (0)PR10 (19)^b^3 (16)1 (17)6 (26)0 (0)SD, *n* (%)29 (54)9 (47)3 (50)12 (52)5 (83)PD, *n* (%)13 (24)7 (37)2 (33)3 (13)1 (17)Abbreviations: CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease^a^Tumor types: bladder carcinoma (patient received prior platinum therapy) and endometrial cancer (patient received both platinum and taxane as prior therapy)^b^Tumor types: biphasic hepatocellular carcinoma and cholangiocarcinoma, breast cancer, cholangiocarcinoma, follicular dendritic cell sarcoma, salivary gland carcinoma, squamous cell carcinoma of the head and neck not otherwise specified, squamous cell carcinoma of the oropharynx, squamous non-small cell lung cancer, and parotid gland carcinoma

In arm 2, among 23 response-evaluable patients, eight patients achieved a PR or complete response (CR; ORR 35%). Two patients with bladder cancer and endometrial cancer receiving pevonedistat 20 mg/m^2^ (MTD) achieved a CR; at data cutoff, the duration of CR was 8.1 and 8.5 months (9 and 11 cycles), respectively. At the time of reporting, both patients remained on study (cycle 43+ representing the longest treatment duration) receiving single-agent pevonedistat since cycle 9 and 13, respectively. Of the six patients achieving PRs in arm 2, two received pevonedistat 25 mg/m^2^ and four received pevonedistat 20 mg/m^2^; all six had progressive disease after PR.

Median duration of response (DOR) for the 12 patients achieving a CR or PR across both arms was 5.9 months (range, 0.03--12.02). Median DOR for the eight patients receiving pevonedistat with carboplatin and paclitaxel (arm 2) was 7.4 months (range, 2.37--12.02). Across 54 response-evaluable patients, 41 achieved stable disease or better (≥SD), of whom 25 received treatment for ≥5 cycles (eight in arm 1, 15 in arm 2, and two in arm 3), with the longest treatment duration being 21 cycles at data cutoff (arm 2, chondrosarcoma). At the pevonedistat MTDs, 10 of 16 patients in arm 1 (25 mg/m^2^) and all 12 patients in arm 2 (20 mg/m^2^) achieved ≥SD; of these, six and nine patients, respectively, received study treatment for ≥5 cycles.

Prior therapies in patients achieving a response are presented in the Online Resource: Supplementary Table [4](#MOESM1){ref-type="media"}. Of 12 patients achieving a CR or PR, 10 had received prior platinum therapy. None of the responders in arm 1 (pevonedistat plus docetaxel) had received prior docetaxel, and one patient had received prior carboplatin plus paclitaxel. By contrast, all but one patient achieving a CR or PR in arm 2 (pevonedistat in combination with carboplatin and paclitaxel) and one responder in arm 2a (pevonedistat plus carboplatin) had received ≥1 course of platinum and/or taxane. In arm 2, four patients had received both taxane and platinum as prior therapies.

ERCC1 expression {#Sec11}
----------------

ERCC1 expression levels were determined by calculating the *H*-score in patients receiving pevonedistat 20 mg/m^2^ or 15 mg/m^2^ in arm 2 and arm 2a. The median *H*-score for all ERCC1-evaluable patients (*n* = 21) was 170 (range, 65--290), which served as the cutoff to classify patients into ERCC1 high (*H*-score \> 170, *n* = 10) and low (*H*-score ≤170, *n* = 11) expression level groups. High ERCC1 expression appeared to correlate with clinical benefit (CR/PR/SD duration ≥5 cycles; Fig. [2](#Fig2){ref-type="fig"}a). There was a trend for patients with high ERCC1 levels to remain on study longer than patients with low ERCC1, with a median time on study of 10.5 and 4.7 months, respectively (Fig. [2](#Fig2){ref-type="fig"}b).Fig. 2Correlation between baseline ERCC1 expression levels\* and (**a**) clinical benefit (CR/PR/durable SD ≥5 cycles) or (**b**) time on study. (**a**) \*ERCC1 staining intensity was determined by immunohistochemistry and the *H*-score was calculated. The median *H*-score of 170 for the ERCC1-evaluable patient population (*n* = 21) was used as the cutoff to dichotomize patients into ERCC1 high (*H-*score \> 170, *n* = 10) and low (*H*-score ≤170, *n* = 11) expression level groups. (**b**) The black horizontal lines inside the boxes represent the median time on study for the ERCC1 high and low expression level groups. Time on study (months) was defined as follows: (last study visit date -- first dose date +1)/30.4375. This was 10.5 and 4.7 months for patients with ERCC1 high and low expression levels, respectively. Box plots represent interquartile range. Outliers are indicated by the highlighted circles. CR, complete response; ERCC1, Excision repair cross-complementation group 1; PD, progressive disease; PR, partial response; SD, stable disease

Discussion {#Sec12}
==========

This phase Ib study was the first to investigate the safety and tolerability of pevonedistat plus standard-of-care chemotherapies in patients with advanced solid tumors. The MTD for pevonedistat was determined to be 25 mg/m^2^ with docetaxel and 20 mg/m^2^ with carboplatin plus paclitaxel. The combination of pevonedistat plus gemcitabine was deemed intolerable due to two patient withdrawals and one on-study death (febrile neutropenia), and based on patients missing ≥1 treatment dose (cycle 1) or experiencing gemcitabine-related myelosuppression which led to dose delays in cycle 2. Therefore, enrollment into this cohort ceased. The most frequently reported DLTs across all arms included grade 3 febrile neutropenia and increased ALT/AST; AST/ALT elevations were reversible with dose holds, reductions, or delays.

The safety profile of pevonedistat plus docetaxel or carboplatin plus paclitaxel was generally favorable. Common AEs reported in this study (fatigue, nausea, anemia, constipation, and diarrhea) were similar to those previously observed in patients receiving standard-of-care chemotherapies \[[@CR27]--[@CR29]\]. With dose reductions or delays, repeat dosing of pevonedistat plus docetaxel or pevonedistat in combination with carboplatin plus paclitaxel was feasible in patients with solid tumors, and at the time of reporting, two patients (arm 2) remained on study receiving single-agent pevonedistat 20 mg/m^2^ (currently cycle 43+). Pevonedistat treatment did not appear to result in additional toxicity when added to standard-of-care chemotherapy, and there was no cumulative toxicity from pevonedistat despite prolonged treatment.

Evaluation of concentration-time data from 58 patients for whom blood samples were available revealed that the pharmacokinetic profile of pevonedistat was unchanged in the presence of docetaxel or gemcitabine compared with historical single-agent pevonedistat pharmacokinetic data \[[@CR7]--[@CR9], [@CR11]\]. There was a trend toward higher pevonedistat plasma concentrations when given with carboplatin plus paclitaxel, compared with single-agent administration. This apparent drug-drug interaction effect, which cannot be explained at this time, warrants further investigation. Although some overlap exists in the metabolizing enzymes and/or transporter proteins involved in the drug clearance of pevonedistat and the standard-of-care agents, none are known inhibitors or inducers. A radiolabeled mass balance study is ongoing to characterize the clearance pathways of pevonedistat in humans ([ClinicalTrials.gov](http://clinicaltrials.gov) identifier NCT03057366). Additionally, because of the limited pharmacokinetic sampling scheme used in this study, individual concentration-time data will be pooled with other study data and analyzed using a population modeling approach to quantify the observed effects of carboplatin and paclitaxel on pevonedistat pharmacokinetics.

The combination of pevonedistat with carboplatin plus paclitaxel (arm 2) showed the most promising broad-based antitumor activity in pretreated patients (≥1 prior therapies). Notably, all but one of the eight responders in arm 2 and one responder in arm 2a had previously received platinum, taxanes, or both. The ORR in arm 2 was 35%, including two patients with CR (bladder cancer and endometrial carcinoma). These two patients discontinued carboplatin plus paclitaxel chemotherapy at cycle 9 and 13, respectively, and went on to maintenance therapy with single-agent pevonedistat; both patients are currently continuing treatment in cycle 43 without evidence of disease. Consistent with preclinical studies reporting synergy between pevonedistat and standard-of-care chemotherapy \[[@CR13], [@CR24]\], the long treatment durations in this study and objective responses in patients resistant to prior platinum/taxane therapy suggest the potential reversal of resistance by the addition of pevonedistat. Further exploration of pevonedistat and carboplatin plus paclitaxel in the platinum- and/or taxane-resistant setting is warranted.

Pevonedistat was shown in model systems to synergize with platinum-containing agents by interfering with NER and ICR pathways \[[@CR13]\]. Previous studies reported that low ERCC1 expression is associated with clinical benefit in advanced cancer patients receiving platinum-based chemotherapy \[[@CR19]--[@CR21]\]. Interestingly, in our study, patients receiving pevonedistat plus paclitaxel and carboplatin, who had high ERCC1 expression appeared to show greater clinical benefit and remained on study longer than those with low ERCC1 expression. Further investigations are warranted to provide insight into this observation, which suggests the possibility that pevonedistat might re-sensitize patients to platinum-based chemotherapy and provide a potential new approach to therapy in these patients.

The observed clinical benefit in patients treated in arm 2, especially in patients with prior taxane and/or platinum exposure, supports further investigation of pevonedistat with carboplatin plus paclitaxel in phase II trials.
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